Compare GIS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | UTHR |
|---|---|---|
| Founded | 1866 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 21.4B |
| IPO Year | N/A | 1999 |
| Metric | GIS | UTHR |
|---|---|---|
| Price | $44.24 | $466.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | $53.27 | ★ $498.83 |
| AVG Volume (30 Days) | ★ 8.2M | 346.5K |
| Earning Date | 03-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | 0.65 | ★ 16.08 |
| EPS | 4.63 | ★ 26.38 |
| Revenue | ★ $18,776,700,000.00 | $3,128,400,000.00 |
| Revenue This Year | N/A | $13.64 |
| Revenue Next Year | N/A | $5.66 |
| P/E Ratio | ★ $9.66 | $18.08 |
| Revenue Growth | N/A | ★ 13.50 |
| 52 Week Low | $42.79 | $266.98 |
| 52 Week High | $67.35 | $519.99 |
| Indicator | GIS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 39.73 |
| Support Level | $44.29 | $464.16 |
| Resistance Level | $44.88 | $479.41 |
| Average True Range (ATR) | 0.98 | 10.35 |
| MACD | 0.07 | -1.47 |
| Stochastic Oscillator | 48.25 | 21.75 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.